Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR ( Diazoxide Choline ) Extended-Release Tablets in Prader-Willi Syndrome

3 weeks ago

PDUFA target action date set for December ...

Ticker	Sentiment	Impact
SLNO	Neutral	8 %